5-[[4-[2-[(E)-1-(6-phenylpyridin-3-yl)ethylideneamino]oxyethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-[[4-[2-[(E)-1-(6-phenylpyridin-3-yl)ethylideneamino]oxyethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• 化学式: C₂₅H₂₃N₃O₄S
• 分子量: 461.5
• InChiKey: NQMQRRVMTPZWOL-OGLMXYFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  115
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Oxime derivatives, their preparation and their therapeutic use
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0708098A1

  公开（公告）日：1996-04-24

  Compounds of formula (I) : in which: R¹ is hydrogen or alkyl; R is alkylene; R³ is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N-R⁴, in which R⁴ is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd) : and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.

  式(I)化合物： 其中R¹ 是氢或烷基；R 是亚烷基；R³ 是氢、烷基、烷氧基、烷硫基、卤素、硝基、氨基、单烷基氨基、二烷基氨基、芳基或芳烷基；X 是芳基或芳香杂环；Y 是氧、硫或式 >N-R⁴ 的基团，其中 R⁴ 是氢、烷基或酰基；Z 是式 (Za)、(Zb)、(Zc) 或 (Zd) 的基团： 本发明化合物及其盐类可用于治疗或预防高脂血症、高血糖、肥胖症、糖耐量受损（IGT）、胰岛素抵抗性非糖耐量受损（NGT）、非诊断性糖耐量、胰岛素抵抗、糖尿病并发症、脂肪肝、多囊卵巢综合征（PCOS）和妊娠糖尿病（GDM）等引起的疾病；此外，本发明化合物还具有醛糖还原酶抑制活性。
• PHENYLALKYLCARBOXYLIC ACID DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP0916651A1

  公开（公告）日：1999-05-19

  Phenylalkylcarboxylic acid derivatives of the general formula: wherein R1 represents an alkyl group and the like, R2 represents an alkylene group, R3 represents a hydrogen atom and the like, X represents a substituted or unsubstituted aryl group and the like, Y represents an oxygen atom and the like, Z represents an alkylene group and the like, and W represents an alkyl group and the like), the pharmacologically acceptable salts thereof or the pharmacologically acceptable esters thereof are useful as therapeutic or preventive agents for hyperglycemia and the like.

  通式如下的苯基烷基羧酸衍生物 其中 R1 代表烷基等，R2 代表亚烷基等，R3 代表氢原子等，X 代表取代或未取代的芳基等，Y 代表氧原子等，Z 代表亚烷基等，W 代表烷基等）、 其药理学上可接受的盐类或其药理学上可接受的酯类可用作高血糖等的治疗或预防剂。
• Composition for use in the treatment and prevention of hyperuricemia
  申请人：Sankyo Company Limited

  公开号：EP0919232A1

  公开（公告）日：1999-06-02

  Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

  曲格列酮等胰岛素敏感性增强剂具有治疗和/或预防高尿酸血症的能力，因此可用于痛风、尿路结石、高尿酸血症肾病和莱希-尼汉综合征等疾病的治疗或预防。
• REMEDY FOR AUTOIMMUNE DISEASES
  申请人：Sankyo Company, Limited

  公开号：EP0953355A1

  公开（公告）日：1999-11-03

  A preventive or therapeutic agent for autoimmune diseases (excluding type I diabetes) contaning an insulin resistance improving substance as an active ingredient.

  一种预防或治疗自身免疫性疾病（I 型糖尿病除外）的制剂，含有一种改善胰岛素抵抗的物质作为活性成分。
• US5972959A
  申请人：——

  公开号：US5972959A

  公开（公告）日：1999-10-26